MedPath

Toronto Metropolitan University

🇨🇦Canada
Ownership
-
Established
1948-01-01
Employees
-
Market Cap
-
Website
http://www.ryerson.ca/

Semaglutide Shows Promise in Reducing Alcohol Consumption and Cravings

• A new study reveals that semaglutide, known as Ozempic and Wegovy, significantly reduces alcohol cravings and consumption in individuals with alcohol use disorder. • Participants on semaglutide experienced fewer heavy drinking days and decreased alcohol intake during lab tests compared to those on a placebo, indicating potential therapeutic benefits. • The research suggests semaglutide's effects on alcohol cravings may surpass existing treatments, offering a promising avenue for addressing the unmet needs in alcohol use disorder. • Further studies are warranted to explore semaglutide's long-term efficacy, optimal dosages, and safety, particularly for individuals without obesity or diabetes.
© Copyright 2025. All Rights Reserved by MedPath